THE EFFECT OF MESOGLYCAN IN PATIENTS WITH CEREBROVASCULAR-DISEASE - APSYCHOMETRIC EVALUATION

Mesoglycan is a preparation of natural glycosaminoglycans, containing mainly heparan sulphate and dermatan sulphate. A clinical trial was co nducted to evaluate the efficacy and the tolerability of once-daily me soglycan in 30 patients with clinical evidence of cerebrovascular insu fficiency. Clinical effectiveness was assessed using psychometric and neurological scales: Sandoz Clinical Assessment for Geriatric Patients (SCAG); Parkside Behaviour Rating Scale Modified; Geriatric Depressio n Scale; and Anxiety Evaluation. Mesoglycan was given as a single oral once-daily dose of 100 mg for a period of 6 months. This treatment wa s shown to have positive effects on the cognitive and behavioural para meters evaluated. The effects on SCAG were already evident after 3 mon ths' treatment and a significant improvement was observed after 6 mont hs in those patients with a moderate to severe disease. During the tre atment period only one patient suffered an adverse reaction attributed to the drug investigated.